Daisuke Tomita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daisuke Tomita has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Yuji Nozaki
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
4 shared publications - Koji Kinoshita
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Sakai, Japan
3 shared publications - Iku Shirasugi
Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Kobe
2 shared publications - Kosuke Ebina
Department of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine Faculty of Medicine , Suita
2 shared publications - Motomu Hashimoto
Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
2 shared publications - Shinya Rai
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
2 shared publications
Latest Publications
- 28 October 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Comparative effectiveness and safety of five Janus kinase inhibitors in real-world clinical practice: the multicentre ANSWER cohort
Objectives: To compare treatment effectiveness and safety among five Janus kinase inhibitors (JAKi) in patients with RA and to identify factors associated with treatment discontinuation in real-world clinical practice. Methods: This retrospective multicentre study used data from the ANSWER (Kansai Consortium for Well-being of Rheumatic Disease Patients) cohort in Japan. RA treatment courses initiating tofacitinib, baricitinib, peficitinib, upadacitinib or filgotinib between 2013 and 2025 were included. Treatment discontinuation due to ineffectiveness and adverse events was evaluated using Kaplan–Meier analysis and multivariable Cox proportional hazards models with multiple imputation. Analyses were adjusted for patient, disease and treatment characteristics, including prior treatment history. Results: A total of 1798 treatment courses from 1240 patients were analysed. Discontinuation risk due to ineffectiveness was lower with upadacitinib [hazard ratio (HR) 0.33, 95% CI 0.24–0.47] and filgotinib (HR 0.59, 95% CI 0.42–0.85) than with tofacitinib (reference), baricitinib (HR 0.82, 95% CI 0.63–1.06) and peficitinib (HR 1.23, 95% CI 0.89–1.70). Differences in discontinuation due to adverse events were observed only between upadacitinib (HR 0.57, 95% CI 0.38–0.85) and peficitinib (reference). Prior IL-6i or JAKi use increased ineffectiveness-related discontinuation for tofacitinib, baricitinib and peficitinib, but not upadacitinib (IL-6i/JAKi: HR 0.67/1.14, 95% CI 0.38–1.16/0.65–1.98) or filgotinib (HR 0.83/1.38, 95% CI 0.45–1.53/0.72–2.65). Conclusion: Treatment effectiveness and safety differed among JAKi in real-world clinical practice. Upadacitinib and filgotinib were associated with higher treatment persistence, and the adverse impact of prior IL-6i or JAKi exposure was not evident for these agents.
- 28 October 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Comparative effectiveness and safety of five Janus kinase inhibitors in real-world clinical practice: the multicentre ANSWER cohort
Objectives: To compare treatment effectiveness and safety among five Janus kinase inhibitors (JAKi) in patients with RA and to identify factors associated with treatment discontinuation in real-world clinical practice. Methods: This retrospective multicentre study used data from the ANSWER (Kansai Consortium for Well-being of Rheumatic Disease Patients) cohort in Japan. RA treatment courses initiating tofacitinib, baricitinib, peficitinib, upadacitinib or filgotinib between 2013 and 2025 were included. Treatment discontinuation due to ineffectiveness and adverse events was evaluated using Kaplan–Meier analysis and multivariable Cox proportional hazards models with multiple imputation. Analyses were adjusted for patient, disease and treatment characteristics, including prior treatment history. Results: A total of 1798 treatment courses from 1240 patients were analysed. Discontinuation risk due to ineffectiveness was lower with upadacitinib [hazard ratio (HR) 0.33, 95% CI 0.24–0.47] and filgotinib (HR 0.59, 95% CI 0.42–0.85) than with tofacitinib (reference), baricitinib (HR 0.82, 95% CI 0.63–1.06) and peficitinib (HR 1.23, 95% CI 0.89–1.70). Differences in discontinuation due to adverse events were observed only between upadacitinib (HR 0.57, 95% CI 0.38–0.85) and peficitinib (reference). Prior IL-6i or JAKi use increased ineffectiveness-related discontinuation for tofacitinib, baricitinib and peficitinib, but not upadacitinib (IL-6i/JAKi: HR 0.67/1.14, 95% CI 0.38–1.16/0.65–1.98) or filgotinib (HR 0.83/1.38, 95% CI 0.45–1.53/0.72–2.65). Conclusion: Treatment effectiveness and safety differed among JAKi in real-world clinical practice. Upadacitinib and filgotinib were associated with higher treatment persistence, and the adverse impact of prior IL-6i or JAKi exposure was not evident for these agents.
- Open Access
- 29 September 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (11) , 6583-6593
Renal function–adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study
- 29 September 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (11) , 6583-6593
Open AccessRenal function–adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study
- Open Access
- 31 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Diagnostic performance of HScore for macrophage activation syndrome complicating Still’s disease in adults: a multicentre case–control study
Objectives: To validate the diagnostic performance of the HScore for Still’s disease (SD)-associated macrophage activation syndrome (MAS; SD-MAS) in adults compared with those of the HLH-2004 diagnostic criteria used with modifications (HLH-04) and the 2016 EULAR/ACR/PRINTO classification criteria for systemic juvenile idiopathic arthritis-associated MAS (MAS-2016). Methods: This multicentre case–control study, conducted at three medical centres in Japan between 2004 and 2023, enrolled patients ≥16 years with active SD and allocated them into SD without MAS and SD-MAS groups by an expert panel. For each patient, we calculated the HScore, HLH-04, MAS-2016 and modified HScore, which excluded haemophagocytosis on bone marrow aspirate. Receiver operating characteristic curve analysis was used to assess the discriminative ability of each criterion. Logistic regression analysis was performed separately for ‘model-1’ (HScore and HLH-04) and ‘model-2’ (MAS-2016 and modified HScore). Results: This study included 86 patients with SD, 25 of whom had SD-MAS. The HScore showed the best area under the curve at 0.991 (95% CI 0.977–1.000), with a cut-off value of 192 (sensitivity, 96.0%; specificity, 96.7%). The optimal cut-off for the modified HScore was 171 (sensitivity, 92.0%; specificity, 83.6%). Multivariate analysis identified only the HScore in model-1 [odds ratio (OR) 1.271; 95% CI 1.006–1.606], whereas both MAS-2016 (OR 4.249; 95% CI 1.636–11.041) and modified HScore (OR 1.066; 95% CI 1.017–1.118) were identified in model-2. Conclusions: The HScore and modified HScore could be useful tools for diagnosing SD-MAS in adults with and without bone marrow aspiration, respectively.
- 31 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Open AccessDiagnostic performance of HScore for macrophage activation syndrome complicating Still’s disease in adults: a multicentre case–control study
Objectives: To validate the diagnostic performance of the HScore for Still’s disease (SD)-associated macrophage activation syndrome (MAS; SD-MAS) in adults compared with those of the HLH-2004 diagnostic criteria used with modifications (HLH-04) and the 2016 EULAR/ACR/PRINTO classification criteria for systemic juvenile idiopathic arthritis-associated MAS (MAS-2016). Methods: This multicentre case–control study, conducted at three medical centres in Japan between 2004 and 2023, enrolled patients ≥16 years with active SD and allocated them into SD without MAS and SD-MAS groups by an expert panel. For each patient, we calculated the HScore, HLH-04, MAS-2016 and modified HScore, which excluded haemophagocytosis on bone marrow aspirate. Receiver operating characteristic curve analysis was used to assess the discriminative ability of each criterion. Logistic regression analysis was performed separately for ‘model-1’ (HScore and HLH-04) and ‘model-2’ (MAS-2016 and modified HScore). Results: This study included 86 patients with SD, 25 of whom had SD-MAS. The HScore showed the best area under the curve at 0.991 (95% CI 0.977–1.000), with a cut-off value of 192 (sensitivity, 96.0%; specificity, 96.7%). The optimal cut-off for the modified HScore was 171 (sensitivity, 92.0%; specificity, 83.6%). Multivariate analysis identified only the HScore in model-1 [odds ratio (OR) 1.271; 95% CI 1.006–1.606], whereas both MAS-2016 (OR 4.249; 95% CI 1.636–11.041) and modified HScore (OR 1.066; 95% CI 1.017–1.118) were identified in model-2. Conclusions: The HScore and modified HScore could be useful tools for diagnosing SD-MAS in adults with and without bone marrow aspiration, respectively.
- Open Access
- 3 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis
Objectives: Glucocorticoid (GC)- and MTX-sparing strategies are clinically important in RA, yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset—late-onset RA (LORA) vs young-onset RA (YORA)—also remains unclear. This study aimed to compare the effectiveness and safety of SAR and JAKi in patients with LORA and YORA. Methods: We conducted a multicentre real-world cohort study of adults with RA initiating SAR or a JAKi. Outcomes over 12 months included change from baseline in MTX dose (ΔMTX, mg/week) and GC dose (ΔGC, mg/day), cumulative treatment discontinuation and change in Clinical Disease Activity Index (CDAI). Analyses were performed within LORA and YORA strata, and propensity score matching (PSM) was applied separately in each stratum to balance baseline characteristics. Sensitivity analyses were conducted in the matched cohorts. Results: Both SAR and JAKi were associated with progressive tapering of concomitant MTX and GC during follow-up. SAR was associated with a higher frequency of MTX discontinuation compared with JAKi. In contrast, GC discontinuation and CDAI improvement were broadly similar between treatments across age strata and MTX subgroups. Findings were consistent after PSM and in sensitivity analyses within both LORA and YORA. Conclusion: In routine clinical practice, SAR and JAKi support de-escalation of concomitant therapy. SAR may permit earlier MTX withdrawal without loss of disease control, with comparable GC tapering and disease activity improvement in both LORA and YORA.
- 3 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Open AccessComparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis
Objectives: Glucocorticoid (GC)- and MTX-sparing strategies are clinically important in RA, yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset—late-onset RA (LORA) vs young-onset RA (YORA)—also remains unclear. This study aimed to compare the effectiveness and safety of SAR and JAKi in patients with LORA and YORA. Methods: We conducted a multicentre real-world cohort study of adults with RA initiating SAR or a JAKi. Outcomes over 12 months included change from baseline in MTX dose (ΔMTX, mg/week) and GC dose (ΔGC, mg/day), cumulative treatment discontinuation and change in Clinical Disease Activity Index (CDAI). Analyses were performed within LORA and YORA strata, and propensity score matching (PSM) was applied separately in each stratum to balance baseline characteristics. Sensitivity analyses were conducted in the matched cohorts. Results: Both SAR and JAKi were associated with progressive tapering of concomitant MTX and GC during follow-up. SAR was associated with a higher frequency of MTX discontinuation compared with JAKi. In contrast, GC discontinuation and CDAI improvement were broadly similar between treatments across age strata and MTX subgroups. Findings were consistent after PSM and in sensitivity analyses within both LORA and YORA. Conclusion: In routine clinical practice, SAR and JAKi support de-escalation of concomitant therapy. SAR may permit earlier MTX withdrawal without loss of disease control, with comparable GC tapering and disease activity improvement in both LORA and YORA.